WaveGuide Corporation Launches World’s First Portable NMR Device

WaveGuide Corporation today launched its new WaveGuide Formµla™, the world’s only battery-powered, compact scientific instrument that performs rapid screening and diagnostics of solid and liquid substances spanning an array of markets and applications.

The WaveGuide Formla™ micro NMR delivers performance as good or better than larger, more costly benchtop NMRs, in a portable, easy-to-use device making it ideal for applications requiring in-situ decision making, including pharmaceutical, petrochemical, food quality, food safety, and consumer product authentication applications. The WaveGuide Formla™ provides quantitative analysis for a wide range of real-world scenarios—from detecting impurities in lubricants indicative of engine and component wear to authenticating biological therapies and vaccines to rapidly screening patients for specific disease states.

The WaveGuide Formla™ represents a significant departure from large, expensive, benchtop NMR solutions. In addition to trained operators, benchtop NMR systems can require up to 24 hours for the device and sample to temperature stabilize. The WaveGuide Formla™ requires minimal user training and little to no sample preparation. After a quick internal calibration, the instrument is ready to use within seconds.

The WaveGuide Formla™ will be launched at Pittcon 2020 booth #4911 in Chicago Illinois, March 2-5, 2020. A technical presentation, “Portable Forensic Analysis of Biological Agents and Consumer Products,” will be delivered by WaveGuide’s Head of Biology, Massimiliano La Colla Ph.D., at the conference on March 4.

“Until now, the size, cost and complexity of commercially available NMR platforms has limited their use to low volume and niche applications with high fixed costs. From WaveGuide’s founding in 2015, we have worked diligently to change this paradigm, partnering with Harvard University’s Department of Physics to pioneer a new class of micro NMR analyzer technology,” said Nelson K. Stacks, CEO and President of WaveGuide Corporation. “The WaveGuide Formla™ is truly a revolutionary development, opening the door to a range of in-situ applications in healthcare, consumer products, and industrial products that were previously impractical or impossible with the existing NMR technology.”

The WaveGuide Formla™ micro NMR is based on patented technology that enables small, low-cost, inhomogeneous magnets to produce a handheld chemical analyzer based on NMR, amplifying the NMR signal-to-noise by a factor of 10,000. WaveGuide has applied for six additional patents, bolstering the core technology.

More on the features and benefits can be found here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version